Do the efficacy of BP-C1 correlate to receptor status in patients suffering from metastatic breast cancer stage IV?

e12581

Background: Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic is currently evaluated in clinical trials for treatment of metastatic breast cancer (MBC) patients. The RECIST was used for evaluation of the target lesions and the sum diameter of the five largest target lesions was measured. BP-C1 inhibits tumor growth, improves quality of life with only few mild to moderate adverse events. The aim was to investigate the correlation between the efficacy of BP-C1 and the receptor status of Estrogen (ER), Progesterone (PR) and Human epidermal growth factor (HER-2) Methods: The material consists of prospectively collected results from 30 Thai and 30 Russian MBC patients included in two randomized and double-blinded controlled clinical trial with stratified semi-cross-over design. The patients received daily IM injections of 0.035mg/ml bw BP-C1 for 32 days. The results from Russia available by March 2017, and will be included in the final presentation Results: Negative ER recorded in 13 patients and positive in 15. During 32 days of BP-C1 treatment, the sum lesion diameters reduces with 1.9 % in the negative receptor group, but increases with 8.0 % among the positive. Similar pattern also detected regarding the PR. Negative PR detected in 17 patients and positive in 12. No changes (0.1%) in the sum lesion diameter found in the group with negative PR, but an increase of 8.8% in the positive group. Negative HER-2 receptor recorded in 13 patients and positive in 13. The sum lesion diameter increases with 7% in the negative group and 6.0% in the positive. In five patients, all the three receptors were positive, 10 patients had one negative receptor, 12 had two negative and three were triple negative. During the 32 days of BP-C1 treatment, the sum lesions increases by 20.7% in the triple positive group and by 7.6% in the group with one negative receptor. In the patients with two or three negative receptors, the sum lesion diameter was unchanged; -0.6% and 0.5%, respectively. The reduction sum lesion diameter seem to increase with increasing number of negative receptors. Conclusions: These findings indicate that BP-C1 may be an important treatment of stage IV MBC with negative ER, PR or HER-2 receptor.

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

The aims were to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) versus placebo and to investigate the long-term tolerability of BP-C1 in the treatment of patients with metastatic breast cancer.